Core Viewpoint - Shuttle Pharmaceuticals Holdings, Inc. is focused on improving outcomes for cancer patients undergoing radiation therapy and will discuss its future plans and clinical trials in an upcoming investor summit [1][3]. Company Overview - Shuttle Pharmaceuticals, founded in 2012 by faculty members of Georgetown University Medical Center, is a specialty pharmaceutical company dedicated to enhancing cancer treatment outcomes through radiation therapy [4]. - The company's mission is to develop therapies that maximize the effectiveness of radiation therapy while minimizing side effects, aiming to increase cancer cure rates and improve patient quality of life [4]. Upcoming Events - CEO Anatoly Dritschilo will participate in a webcasted fireside chat at the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025, at 3:30 p.m. Eastern time [2][3]. - The webcast will be accessible online, and a replay will be available after the event [2]. Clinical Trials and Developments - Dr. Dritschilo will discuss the progress of the Phase 2 Clinical Trial of Ropidoxuridine for glioblastoma treatment, currently enrolling patients at six cancer centers [3]. - The trial targets patients with IDH wild-type, methylation negative glioblastoma [3]. - Recent developments in Shuttle Diagnostics, particularly the PC-RAD test for predicting outcomes after radiation therapy for localized prostate cancer, will also be addressed [3].
Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025